Recent News

• 06.05.2025 - IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
• 06.03.2025 - IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
• 06.02.2025 - IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
• 05.28.2025 - IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
• 05.27.2025 - IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
• 05.23.2025 - IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
• 05.23.2025 - IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
• 05.22.2025 - IMUNON Announces Withdrawal of Form S-1 Registration Statement
• 05.15.2025 - IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

Recent Filings

• 05.30.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.30.2025 - 8-K Current report
• 05.30.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.30.2025 - PRE 14A Other preliminary proxy statements
• 05.28.2025 - D Notice of Exempt Offering of Securities
• 05.27.2025 - 8-K Current report
• 05.27.2025 - EX-99.1 EX-99.1
• 05.22.2025 - 8-K Current report
• 05.22.2025 - RW Registration Withdrawal Request
• 05.20.2025 - 8-K Current report